Navigation Links
Intellect Neurosciences Issues Letter to Shareholders
Date:10/14/2011

NEW YORK, Oct. 14, 2011 /PRNewswire/ -- Intellect Neurosciences, Inc. (OTCBB: ILNS), a biopharmaceutical company engaged in the discovery and development of disease-modifying therapeutic agents for the treatment of Alzheimer's and other neurological diseases today issued the following Letter to Shareholders from Dr. Daniel Chain, Chairman and CEO.

Dear Shareholder,

I would like to take this opportunity to update you about pertinent corporate and industry developments contemporaneous with the current filing of our quarterly financial statements with the SEC.

Of special note is our recent transaction with ViroPharma Inc., which was announced September 30, 2011. Intellect granted an exclusive license to ViroPharma regarding certain of Intellect's licensed patents and patent applications related to Intellect's clinical stage drug candidate, OX1, an extremely potent antioxidant molecule that has been demonstrated to protect nerve cells in the brain from highly oxidizing neurotoxins. ViroPharma plans to develop and commercialize OX1 as a treatment of Friedreich's Ataxia and possibly other diseases for which OX1 may qualify for orphan drug designation.  Under the terms of the license agreement, Intellect received an upfront payment of $6.5 million, and will receive up to an additional $120 million based on defined events and a tiered royalty of up to a maximum of low double digits based on annual net sales.  In exchange, Intellect transferred to ViroPharma all of Intellect's intellectual property rights, data and know-how, assembled over several years related to its OX1 research and development program.  NYU Medical School and University of South Alabama, which own certain patents in relation to OX1, are entitled to a portion of the revenues received by Intellect from ViroPharma pursuant to an exclusive license agreement between Intellect Neurosciences and those universities.

I am particularly gratified by the interest shown i
'/>"/>

SOURCE Intellect Neurosciences, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related medicine technology :

1. Intellect Neurosciences CEO to be Featured on Wall Street Reporter
2. ViroPharma Licenses Rights From Intellect Neurosciences for Product Candidate for Friedreichs Ataxia
3. IRIDEX Licenses the Exclusive Rights to Ophthalmology Products and Intellectual Property from Ocunetics, Inc.
4. PILMA Vows to Redouble Support for Increased Protections Against Intellectual Property Theft
5. Dehaier Strengthens Intellectual Property Portfolio
6. NMT Medical, Inc. Adds Intellectual Property to Its Sealed Bid Sale of Friday, June 10, 2011 at Twelve OClock Noon
7. GT Life Sciences Broadens Intellectual Property Portfolio with Issuance of U.S. Patent on Core Computational Systems and Methods for Genomic-based Metabolic Modeling
8. Inovio Pharmaceuticals Market-Leading Intellectual Property Recognized by MDB Capital Award
9. NMT Medical, Inc. Sealed Bid Sale of its Intellectual Property to Take Place Friday, June 10, 2011 at Twelve OClock Noon
10. Software Development Firms New Intellectual Property Group, Blue Horseshoe IP Creates Solutions to Help Customers Optimize Supply Chain
11. As Pharmaceutical Supply Chain Goes Global, Threat of Counterfeiting, Intellectual Property Theft and Contamination Rises, Finds New Report; New Supply Chain Management Strategies Needed
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/11/2014)... , July 11, 2014 /PRNewswire-iReach/ -- VAPETEK™, ... a vegetable-glycol solution for use in portable vaporizers, ... the active ingredients in cannabis, cannabidiol offers consumers ... vaporizer devices, and other vaporizer technology. ... Cannabis naturally contains 483 different compounds which are ...
(Date:7/11/2014)... 11, 2014 Patient engagement has become ... organizations are turning to an assortment of marketing ... part of this evolving approach to patient engagement, ... and engage patients throughout their experiences with a ... By mapping the patient journey and employing a ...
(Date:7/11/2014)... 11, 2014 The consumer marketing playbook ... industry sectors to better identify winning tools and ... engage with and understand consumers, as new technologies ... critical purchasing decisions. According to ... one area where organizations can observe a deep ...
Breaking Medicine Technology:VAPETEK Releases CBD-Infused eLiquid For The Consumer Market 2New Study Uses Six-Step Patient Journey as Framework for Consumer-Focused Marketing Opportunities 2New Technologies Transforming Consumer Marketing Research Playbook 2
... Dec. 17 Novavax, Inc.,(Nasdaq: NVAX ) ... recombinant trivalent seasonal influenza virus-like particle (VLP),vaccine. The ... two,influenza vaccine programs that Novavax is developing using ... candidate is,currently in Phase I/IIa clinical trials., ...
... Product Developed Through Joint Venture Between Bristol-Myers Squibb and ... First of Its Kind in HIV Treatment -, ... The European Commission has granted marketing authorization for,ATRIPLA(R) (efavirenz ... ATRIPLA for commercialization in the,27 countries of the European ...
Cached Medicine Technology:Novavax Announces Preclinical Results for Seasonal Influenza Vaccine Program 2Novavax Announces Preclinical Results for Seasonal Influenza Vaccine Program 3European Commission Approves ATRIPLA(R) (efavirenz 600 mg/emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg), the First Once-Daily Single Tablet Regimen for Virologically Suppressed Adults With HIV-1 Infection 2European Commission Approves ATRIPLA(R) (efavirenz 600 mg/emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg), the First Once-Daily Single Tablet Regimen for Virologically Suppressed Adults With HIV-1 Infection 3European Commission Approves ATRIPLA(R) (efavirenz 600 mg/emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg), the First Once-Daily Single Tablet Regimen for Virologically Suppressed Adults With HIV-1 Infection 4European Commission Approves ATRIPLA(R) (efavirenz 600 mg/emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg), the First Once-Daily Single Tablet Regimen for Virologically Suppressed Adults With HIV-1 Infection 5European Commission Approves ATRIPLA(R) (efavirenz 600 mg/emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg), the First Once-Daily Single Tablet Regimen for Virologically Suppressed Adults With HIV-1 Infection 6European Commission Approves ATRIPLA(R) (efavirenz 600 mg/emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg), the First Once-Daily Single Tablet Regimen for Virologically Suppressed Adults With HIV-1 Infection 7European Commission Approves ATRIPLA(R) (efavirenz 600 mg/emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg), the First Once-Daily Single Tablet Regimen for Virologically Suppressed Adults With HIV-1 Infection 8European Commission Approves ATRIPLA(R) (efavirenz 600 mg/emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg), the First Once-Daily Single Tablet Regimen for Virologically Suppressed Adults With HIV-1 Infection 9
(Date:7/12/2014)... "The second toes cross over the big toes on my ... an inventor from East Hartford, Conn. This gave him idea ... He then created a prototype of the Comfort Sock, which ... toes from overlapping. This avoids discomfort and pain, which allows ... use, it's ideal for people with foot problems, athletes and ...
(Date:7/12/2014)... 2014 Sean Francis, owner of the Kawartha Lakes ... to his clients. He’s also known for his support of local ... way to combine the two and is excited to announce that ... Boys and Girls Club. , The funds are the result of ... 23rd. Francis sent out emails and asked his clients to put ...
(Date:7/12/2014)... “After my mom’s stroke, she loss the use of her ... use of his left side. Eating became a difficult task for ... like them enjoy eating again,” said an inventor, from Fayetteville, N.C. ... HALL PLATE (P C H PLATE). , The PATRICIA CAROL HALL ... eat for individuals who suffer from stroke, experience tremors or loss ...
(Date:7/12/2014)... 12, 2014 Using and carrying around ... two inventors from Ashland, Va., decided that there needed ... inspired us to conceive of our design," he said. ... KIDNEY KOVER, which provides an inconspicuous way to use ... as well as promotes comfort and peace of mind. ...
(Date:7/12/2014)... New York (PRWEB) July 12, 2014 ... to move forward in U.S. courts, Bernstein Liebhard LLP ... elevated metal ion levels to the failure of metal-on-metal ... 2nd issue of The Journal of Bone & Joint ... received unilateral Articular Surface Replacement prostheses at least twelve ...
Breaking Medicine News(10 mins):Health News:Kawartha Lakes Fit Body Boot Camp’s Successful Fat Loss Challenge Results in $2,000 to Boys and Girls Club 2Health News:Kawartha Lakes Fit Body Boot Camp’s Successful Fat Loss Challenge Results in $2,000 to Boys and Girls Club 3Health News:DePuy Pinnacle Hip Lawsuit News: Bernstein Liebhard LLP Notes Release of New Study Tying Elevated Metal Ions to Metal-on-Metal Hip Failure 2Health News:DePuy Pinnacle Hip Lawsuit News: Bernstein Liebhard LLP Notes Release of New Study Tying Elevated Metal Ions to Metal-on-Metal Hip Failure 3Health News:DePuy Pinnacle Hip Lawsuit News: Bernstein Liebhard LLP Notes Release of New Study Tying Elevated Metal Ions to Metal-on-Metal Hip Failure 4
... with effects of prescription drugs for heart troubles, researcher says ... of Americans who are taking traditional herbal medications for heart ... new report says. , "They may be safe," said Dr. ... Arizona, and author of a report in the Feb. 9 ...
... ... ability to convert into a stylish, comfortable footrest , ... Las Vegas (PRWEB) February 1, 2010 -- ... Chair® Recliners and other wellness solutions, announced today the introduction of its new and ...
... androgen deprivation, official says , MONDAY, Feb. 1 ... the physicians who treat them are being warned ... the malignancy might increase the risk of heart ... substantial amount of data demonstrating that ADT adversely ...
... scored lowest on test also had worst outcomes, study reports, ... or thinking abilities could signal an increased likelihood for a ... men who were not diagnosed as having dementia but who ... greatly increased risk for stroke. , It,s not yet clear ...
... , Less serious recurrence seen with Ponseti casting method , ... in a thousand babies born in the United States , but ... feet compatible with an active, normal lifestyle. A new study in the ... Joint Surgery (JBJS) compared two common treatment options for clubfoot – ...
... , GREENWOOD VILLAGE, Colo. , Feb. ... revenue cycle solutions for the healthcare industry, announced today ... electronic EDI 278 transaction to UnitedHealthcare conforming to new ... UnitedHealthcare requests hospitals to submit EDI notification of each ...
Cached Medicine News:Health News:Herbal Remedies Can Cause Cardiac Problems 2Health News:Herbal Remedies Can Cause Cardiac Problems 3Health News:Human Touch Introduces New CirQlation™ Elite Foot & Calf Massager Providing Ultimate Targeted Relief for Tired Feet and Calves 2Health News:Human Touch Introduces New CirQlation™ Elite Foot & Calf Massager Providing Ultimate Targeted Relief for Tired Feet and Calves 3Health News:Human Touch Introduces New CirQlation™ Elite Foot & Calf Massager Providing Ultimate Targeted Relief for Tired Feet and Calves 4Health News:Experts Issue Warning on Prostate Hormone Therapy 2Health News:Experts Issue Warning on Prostate Hormone Therapy 3Health News:Poor Mental Functioning May Predict Stroke 2Health News:Poor Mental Functioning May Predict Stroke 3Health News:Study Finds Ponseti Method of Clubfoot Correction Leads to Lower Surgical Rates and Less Revision Surgery 2Health News:Study Finds Ponseti Method of Clubfoot Correction Leads to Lower Surgical Rates and Less Revision Surgery 3Health News:Study Finds Ponseti Method of Clubfoot Correction Leads to Lower Surgical Rates and Less Revision Surgery 4Health News:Recondo Technology Announces Omni278 UnitedHealthcare Admission Notification Service 2Health News:Recondo Technology Announces Omni278 UnitedHealthcare Admission Notification Service 3
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
Medicine Products: